• Something wrong with this record ?

Detection of minimal residual disease in lung cancer

J. Chudacek, T. Bohanes, J. Klein, A. Benedikova, J. Srovnal, M. Szkorupa, P. Skalicky, J. Skarda, M. Hajduch, C. Neoral

. 2014 ; 158 (2) : 189-193. [pub] 20130402

Language English Country Czech Republic

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

Grant support
NT14406 MZ0 CEP Register

BACKGROUND: Even after successful radical treatment of lung cancer, patients in stages I and II of the TNM system very frequently suffer recurrence, which end lethally. Detection of subclinical residual disease after surgery is thus one of the most important emerging diagnostic methods. Minimal residual disease (MRD) is defined as the presence of isolated tumor cells or circulating cells in a patient after curative primary tumor removal and at the same time, no clinical signs of cancer. Conventional methods cannot detect minimal residual disease and hence there is a need for detection using new molecular biological methods. METHODS: We searched the PubMed database for original and review articles on minimal residual disease in lung cancer. Search words were "lung cancer", "minimal residual disease" and "detection of minimal residual disease". The publications we found were compared with the results of our own studies on the detection of minimal residual disease in lung cancer and the personal experiences are described. Examination of blood samples from 98 healthy volunteers and bone marrow from 12 patients with non inflammatory and non tumour illness, were used to determine cut-off values for specific markers in the compartments. Subsequently, expression of selected markers in tumor tissue was analysed in a pilot sample of 50 patients with lung cancer and the presence of MRD was measured as expression of values of the tested markers correlated with clinico-pathological characteristics. CONCLUSIONS: Recent studies on other malignancies apart from lung cancer have shown the importance of MRD detection in the determination of disease progression and prognosis. The methods of MRD diagnostics are based on detection of specific tumor markers. Of these, the most specific for lung cancer, appears to be the LunX protein. The best method for determining MRD is probably RT-PCR. Further studies should expand knowledge in this area: to refine understanding of the importance of tumor markers for prognosis, as well as to confirm the significance of these findings in clinical practice.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15033235
003      
CZ-PrNML
005      
20191022090841.0
007      
ta
008      
151016s2014 xr f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2013.019 $2 doi
035    __
$a (PubMed)23558472
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Chudáček, Josef $u Department of Surgery I, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic $7 xx0228773
245    10
$a Detection of minimal residual disease in lung cancer / $c J. Chudacek, T. Bohanes, J. Klein, A. Benedikova, J. Srovnal, M. Szkorupa, P. Skalicky, J. Skarda, M. Hajduch, C. Neoral
520    9_
$a BACKGROUND: Even after successful radical treatment of lung cancer, patients in stages I and II of the TNM system very frequently suffer recurrence, which end lethally. Detection of subclinical residual disease after surgery is thus one of the most important emerging diagnostic methods. Minimal residual disease (MRD) is defined as the presence of isolated tumor cells or circulating cells in a patient after curative primary tumor removal and at the same time, no clinical signs of cancer. Conventional methods cannot detect minimal residual disease and hence there is a need for detection using new molecular biological methods. METHODS: We searched the PubMed database for original and review articles on minimal residual disease in lung cancer. Search words were "lung cancer", "minimal residual disease" and "detection of minimal residual disease". The publications we found were compared with the results of our own studies on the detection of minimal residual disease in lung cancer and the personal experiences are described. Examination of blood samples from 98 healthy volunteers and bone marrow from 12 patients with non inflammatory and non tumour illness, were used to determine cut-off values for specific markers in the compartments. Subsequently, expression of selected markers in tumor tissue was analysed in a pilot sample of 50 patients with lung cancer and the presence of MRD was measured as expression of values of the tested markers correlated with clinico-pathological characteristics. CONCLUSIONS: Recent studies on other malignancies apart from lung cancer have shown the importance of MRD detection in the determination of disease progression and prognosis. The methods of MRD diagnostics are based on detection of specific tumor markers. Of these, the most specific for lung cancer, appears to be the LunX protein. The best method for determining MRD is probably RT-PCR. Further studies should expand knowledge in this area: to refine understanding of the importance of tumor markers for prognosis, as well as to confirm the significance of these findings in clinical practice.
650    _2
$a nemalobuněčný karcinom plic $x krev $x diagnóza $x chirurgie $7 D002289
650    _2
$a glykoproteiny $x genetika $7 D006023
650    _2
$a lidé $7 D006801
650    _2
$a keratin-19 $x genetika $7 D053539
650    _2
$a nádory plic $x krev $x diagnóza $x chirurgie $7 D008175
650    _2
$a reziduální nádor $7 D018365
650    12
$a nádorové cirkulující buňky $7 D009360
650    _2
$a fosfoproteiny $x genetika $7 D010750
650    _2
$a protoonkogenní proteiny c-met $x genetika $7 D019859
650    _2
$a messenger RNA $x krev $7 D012333
650    _2
$a erbB receptory $x genetika $7 D066246
650    _2
$a nádorové biomarkery $x krev $7 D014408
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Bohanes, Tomáš $7 xx0033707 $u Department of Surgery I, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
700    1_
$a Klein, Jiří, $d 1963- $7 xx0047429 $u Department of Surgery, The District Hospital of Tomas Bata, Zlin
700    1_
$a Benedíková, Andrea $7 xx0169440 $u Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc
700    1_
$a Srovnal, Josef $7 xx0091239 $u Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc
700    1_
$a Szkorupa, Marek $7 xx0145985 $u Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc
700    1_
$a Skalický, Pavel $7 xx0102179 $u Department of Surgery I, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
700    1_
$a Škarda, Jozef $7 xx0098446 $u Institute of Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc
700    1_
$a Hajdúch, Marián $7 xx0050218 $u Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc
700    1_
$a Neoral, Čestmír, $d 1952- $7 xx0000421 $u Department of Surgery I, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czech Republic $x 1213-8118 $g Roč. 158, č. 2 (2014), s. 189-193
856    41
$u http://biomed.papers.upol.cz/ $y domovská stránka časopisu
910    __
$a ABA008 $b A 1502 $c 958 $y 4 $z 0
990    __
$a 20151016 $b ABA008
991    __
$a 20191022091315 $b ABA008
999    __
$a ok $b bmc $g 1095633 $s 916366
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 158 $c 2 $d 189-193 $e 20130402 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
GRA    __
$a NT14406 $p MZ0
LZP    __
$b NLK118 $a Pubmed-20151016

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...